ProCeryon Bisosciences
ProCeryon Biosciences GmbH, founded to commercialize in silico protein structure prediction technology developed at the University of Salzburg, Austria, has positioned itself as a niche player in the computational biology space.
Profile
Develops software for protein structure prediction used in drug discovery and biotechnology research.
ProCeryon Biosciences GmbH, founded to commercialize in silico protein structure prediction technology developed at the University of Salzburg, Austria, has positioned itself as a niche player in the computational biology space. The company leverages academic research to offer tools for protein structure prediction, a critical area in drug discovery and biotechnology. ProCeryon's origins trace back to academic collaboration, with its technology rooted in advanced computational methods.
The company has maintained a low profile, focusing on refining its core technology rather than aggressive market expansion. Its product portfolio includes software solutions tailored for researchers in biotechnology and pharmaceuticals, aiming to streamline the protein structure prediction process. Financially, ProCeryon has not disclosed significant funding rounds or revenue figures, suggesting a bootstrapped or modestly funded operation.
The company's headcount remains small, with key personnel like Sebastian S., who has a background in software development, and Alessandro Monge, involved in corporate and business development for AI applications. ProCeryon's market position is characterized by its specialized offerings, catering to a select group of researchers and institutions. The company's website, last updated in 2004, indicates a potential lack of recent updates or advancements, raising questions about its current operational status and technological relevance.
Who buys this
- Biotechnology researchers
- Pharmaceutical companies
- Academic institutions
- Drug discovery teams
Strengths and what to watch
Strengths
- Rooted in academic research from the University of Salzburg
- Specialized in protein structure prediction
- Tailored solutions for biotechnology and pharmaceutical research
Watch for
- Limited financial disclosures and funding history
- Potential lack of recent technological updates
- Small headcount and low market visibility
Key Information
- Founded
- 1993
- Headquarters
- Ithaca, NY
Frequently Asked Questions
What does ProCeryon Biosciences do?
ProCeryon Biosciences develops specialized software for protein structure prediction, primarily used in drug discovery and biotechnology research. The Austria-based company commercializes academic research from the University of Salzburg, offering computational tools to streamline protein modeling for pharmaceutical and academic researchers.
Who uses ProCeryon's protein prediction software?
Their primary customers include biotechnology researchers, pharmaceutical companies, academic institutions, and drug discovery teams. The software caters to professionals needing advanced computational methods for protein structure analysis, particularly in research-driven environments.
How does ProCeryon's technology compare to other protein modeling tools?
ProCeryon positions itself as a niche provider with academic roots, focusing on specialized prediction algorithms rather than broad commercial appeal. Unlike some competitors, it maintains a small-scale operation with tailored solutions, though its technological updates appear limited since 2004.
Is ProCeryon Biosciences still active in 2023?
The company's website hasn't been updated since 2004, raising questions about current operations. With no recent funding announcements or product updates, ProCeryon may be maintaining legacy systems rather than actively developing new technologies in the competitive computational biology space.
What are ProCeryon Biosciences' main strengths?
Key strengths include its academic foundation from the University of Salzburg, specialized protein prediction algorithms, and tailored solutions for research applications. The company's focus on core technology rather than mass-market expansion appeals to specific biotechnology and pharmaceutical research needs.
Has ProCeryon Biosciences received significant funding?
ProCeryon has not disclosed major funding rounds or revenue figures, suggesting either bootstrapped operations or modest financial backing. The small headcount and limited market visibility align with this financial profile, typical of niche academic spin-offs in computational biology.
Sources
- at.linkedin.com — Background on Gerald Stedile's experience in software departments
- at.linkedin.com — Sebastian S.'s role and technologies used at ProCeryon Biosciences
- www.linkedin.com — Alessandro Monge's involvement in corporate and business development for AI applications
- www.proceryon.com — Company website and product information